Ian F. Smith Sells 2,125 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) COO Ian F. Smith sold 2,125 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $155.61, for a total value of $330,671.25. The sale was disclosed in a filing with the SEC, which is available through this link.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.19% during trading on Wednesday, reaching $154.76. The company’s stock had a trading volume of 1,050,665 shares. The company’s 50-day moving average is $154.24 and its 200-day moving average is $136.37. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.85. The stock has a market cap of $39.02 billion, a PE ratio of 148.66 and a beta of 1.73.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The firm had revenue of $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.24 earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/18/ian-f-smith-sells-2125-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.
Institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC grew its holdings in Vertex Pharmaceuticals by 48.6% during the first quarter. Teachers Advisors LLC now owns 510,373 shares of the pharmaceutical company’s stock worth $55,809,000 after buying an additional 166,998 shares in the last quarter. Dynamic Capital Management Ltd grew its holdings in Vertex Pharmaceuticals by 53.8% during the first quarter. Dynamic Capital Management Ltd now owns 39,614 shares of the pharmaceutical company’s stock worth $4,332,000 after buying an additional 13,853 shares in the last quarter. Delta Lloyd Asset Management N.V. bought a new stake in Vertex Pharmaceuticals during the second quarter worth $3,285,000. NorthCoast Asset Management LLC bought a new stake in Vertex Pharmaceuticals during the second quarter worth $782,000. Finally, Prudential Financial Inc. grew its holdings in Vertex Pharmaceuticals by 12.8% during the second quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock worth $57,312,000 after buying an additional 50,350 shares in the last quarter. Institutional investors and hedge funds own 92.82% of the company’s stock.
Several brokerages have weighed in on VRTX. Raymond James Financial, Inc. raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 price objective for the company in a report on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price objective on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. boosted their price objective on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Finally, Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $167.25.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.